Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Steve who wrote (29687)	12/16/1999 9:44:00 AM
From: Henry Niman	Respond to of 32384

Steve, Thanks for the link. Broadcast is about an hour, but details on ONTAK and Targretin come in last 5-10 minutes. ONTAK is described as first FDA approved drug for CTCL and like a guided missile. Data is on patients who have failed several prior therapies and about 1/3 of these patients respond. In some cases "tumors just melt away". Expected even better results in patients treated earlier. Not sure on date of broadcast, but Targretin is described as an exciting new drug that was targeted Vitamin-A derivative (FDA approval not mentioned). Described as "extremely effective" in most cases, "including EARLY cases". The segment was a panel discussion by three physicians who were experts in the field (from MD Anderson, City of Hope, and UCLA) and was a ringing endorsement for LGND and its drug discovery program.